MCRs of intact GLP-1 and GIP , and the GLP-1 metabolite were reduced in dialysis patients on the placebo day ( P < .009 ) , and T1/2 of intact and metabolite forms of GLP-1 and GIP were comparable between groups ( P > .121 ) .